In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Drug Safety Changes: Safe Legislation; Unsafe Climate

Executive Summary

The message from RPM's FDA/CMS Summit Conference: if you want to handicap the effect of the continuing drug safety debate around FDA, you can track the progress of the Kennedy-Enzi bill through Congress - and listen to the tone of the comments from the agency's top managers and its critics. Both will tell you what's at stake for pharma in 2007.

Related Content

Biopharma: Reviewing 2007 to Forecast 2008
Overheard at JP Morgan's 25th Health Care Conference: Making Up for Lost Drugs: Pharma Attempts to Appease Investors
Playing Doctor: The Impact of the Tysabri Risk Plan
Where Have All the New Drugs Gone
Shadow FDA? Researchers Are Taking Approval Matters into their Own Hands


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts